| P50 | author | Laura Kovanda | Q88595470 |
| | William Hope | Q37370273 |
| P2093 | author name string | Amit V Desai | |
| P2860 | cites work | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Rat monoclonal antibodies against Aspergillus galactomannan | Q28316193 |
| | Serum and urine galactomannan testing for screening in patients with hematological malignancies | Q38979166 |
| | Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. | Q40012830 |
| | Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy | Q40186278 |
| | Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis | Q41130252 |
| | MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex | Q41453215 |
| | Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis | Q42234488 |
| | Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis | Q42675899 |
| | Detection of galactomannan for diagnosis of fungal rhinosinusitis | Q42728052 |
| | Invasive pulmonary aspergillosis due to Aspergillus terreus: value of DNA, galactomannan and (1→3)-β-d-glucan detection in serum samples as an adjunct to diagnosis | Q42931900 |
| | Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study | Q43198289 |
| | Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. | Q43517131 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 |
| | Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications | Q45242201 |
| | Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients | Q46422737 |
| | Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis | Q46933151 |
| | Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. | Q47568169 |
| | Aspergillus galactomannan antigenemia in penicilliosis marneffei | Q57610566 |
| | Galactomannan testing might be useful for early diagnosis of fusariosis | Q59294662 |
| | Receptor-mediated clearance of Aspergillus galactomannan | Q68944581 |
| | Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole | Q74106709 |
| | Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease | Q77734361 |
| | Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer | Q80559638 |
| | Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients | Q83131195 |
| | Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response | Q86211431 |
| | Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia | Q28349552 |
| | Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis | Q28540254 |
| | Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing | Q31149815 |
| | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 |
| | Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum. | Q33622932 |
| | Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis | Q33769712 |
| | Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 |
| | Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits | Q34108880 |
| | The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy | Q34290097 |
| | Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis | Q34514484 |
| | Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus | Q34725169 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition | Q35194409 |
| | Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus | Q35385786 |
| | Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model | Q35666627 |
| | Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. | Q35672970 |
| | Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay | Q35806844 |
| | Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. | Q36171643 |
| | Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis | Q36439102 |
| | Changes of serum aspergillus galactomannan during hematopoietic stem cell transplantation in children with prior invasive aspergillosis | Q36668077 |
| | Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy | Q36730105 |
| | Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis | Q36746929 |
| | Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. | Q36826800 |
| | Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis | Q36887855 |
| | Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints | Q36977398 |
| | Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model. | Q37036445 |
| | Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits | Q37119029 |
| | Liposomal amphotericin B: what is its role in 2008? | Q37145210 |
| | Conventional or molecular measurement of Aspergillus load | Q37226612 |
| | Azole resistance in Aspergillus fumigatus: a growing public health concern. | Q38152679 |
| | Micafungin for the treatment of invasive aspergillosis. | Q38183548 |
| | Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity | Q38238216 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 143-151 | |
| P577 | publication date | 2017-02-08 | |
| P1433 | published in | Journal of Pharmacokinetics and Pharmacodynamics | Q15766045 |
| P1476 | title | Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis | |
| P478 | volume | 44 | |